Overview

Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the bioavailability (the extent to which a medication becomes available to the body) of subcutaneously (under the skin using a needle) administered sirukumab and to compare the pharmacokinetics of sirukumab administered subcutaneously using a pre-filled syringe fitted with the UltraSafe Passive™ Delivery system (PFS-U) with the SmartJect™ Autoinjector (PFS-AI) in healthy male participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal